Effect of antiviral therapy in patients with low HBV DNA level on transarterial chemoembolization for hepatocellular carcinoma
Myung Pyo Kim
Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, South Korea
Search for more papers by this authorJae Kook Yang
Department of Internal Medicine, Soonchunhyang University College of Medicine Cheonan Hospital, Cheonan, South Korea
Search for more papers by this authorCorresponding Author
Baek Gyu Jun
Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, South Korea
Department of Internal Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, South Korea
Correspondence
Sae Hwan Lee, Liver clinic, Soonchunhyang University School of Medicine, Cheonan Hospital, 31 Soonchunhyang 6gil, Dongnam-gu, Cheonan, Chungnam, 31151, South Korea.
Email: [email protected]
Baek Gyu Jun, Division of Gastroenterology, Department of Internal Medicine, University of Ulsan College of Medicine, Gangneung Asan Hospital, 38, Bangdong-gil, Sacheon-myeon, Gangneung-si, Gangwon-do, South Korea.
Email: [email protected]
Search for more papers by this authorYoung Don Kim
Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, South Korea
Search for more papers by this authorGab Jin Cheon
Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, South Korea
Search for more papers by this authorHee Jae Jung
Department of Internal Medicine, Soonchunhyang University College of Medicine Bucheon Hospital, Bucheon, South Korea
Search for more papers by this authorJeong-Ju Yoo
Department of Internal Medicine, Soonchunhyang University College of Medicine Bucheon Hospital, Bucheon, South Korea
Search for more papers by this authorSang Gyune Kim
Department of Internal Medicine, Soonchunhyang University College of Medicine Bucheon Hospital, Bucheon, South Korea
Search for more papers by this authorYoung Seok Kim
Department of Internal Medicine, Soonchunhyang University College of Medicine Bucheon Hospital, Bucheon, South Korea
Search for more papers by this authorSoung Won Jeong
Department of Internal Medicine, Soonchunhyang University College of Medicine Seoul Hospital, Seoul, South Korea
Search for more papers by this authorJae Young Jang
Department of Internal Medicine, Soonchunhyang University College of Medicine Seoul Hospital, Seoul, South Korea
Search for more papers by this authorHong Soo Kim
Department of Internal Medicine, Soonchunhyang University College of Medicine Cheonan Hospital, Cheonan, South Korea
Search for more papers by this authorCorresponding Author
Sae Hwan Lee
Department of Internal Medicine, Soonchunhyang University College of Medicine Cheonan Hospital, Cheonan, South Korea
Correspondence
Sae Hwan Lee, Liver clinic, Soonchunhyang University School of Medicine, Cheonan Hospital, 31 Soonchunhyang 6gil, Dongnam-gu, Cheonan, Chungnam, 31151, South Korea.
Email: [email protected]
Baek Gyu Jun, Division of Gastroenterology, Department of Internal Medicine, University of Ulsan College of Medicine, Gangneung Asan Hospital, 38, Bangdong-gil, Sacheon-myeon, Gangneung-si, Gangwon-do, South Korea.
Email: [email protected]
Search for more papers by this authorMyung Pyo Kim
Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, South Korea
Search for more papers by this authorJae Kook Yang
Department of Internal Medicine, Soonchunhyang University College of Medicine Cheonan Hospital, Cheonan, South Korea
Search for more papers by this authorCorresponding Author
Baek Gyu Jun
Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, South Korea
Department of Internal Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, South Korea
Correspondence
Sae Hwan Lee, Liver clinic, Soonchunhyang University School of Medicine, Cheonan Hospital, 31 Soonchunhyang 6gil, Dongnam-gu, Cheonan, Chungnam, 31151, South Korea.
Email: [email protected]
Baek Gyu Jun, Division of Gastroenterology, Department of Internal Medicine, University of Ulsan College of Medicine, Gangneung Asan Hospital, 38, Bangdong-gil, Sacheon-myeon, Gangneung-si, Gangwon-do, South Korea.
Email: [email protected]
Search for more papers by this authorYoung Don Kim
Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, South Korea
Search for more papers by this authorGab Jin Cheon
Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, South Korea
Search for more papers by this authorHee Jae Jung
Department of Internal Medicine, Soonchunhyang University College of Medicine Bucheon Hospital, Bucheon, South Korea
Search for more papers by this authorJeong-Ju Yoo
Department of Internal Medicine, Soonchunhyang University College of Medicine Bucheon Hospital, Bucheon, South Korea
Search for more papers by this authorSang Gyune Kim
Department of Internal Medicine, Soonchunhyang University College of Medicine Bucheon Hospital, Bucheon, South Korea
Search for more papers by this authorYoung Seok Kim
Department of Internal Medicine, Soonchunhyang University College of Medicine Bucheon Hospital, Bucheon, South Korea
Search for more papers by this authorSoung Won Jeong
Department of Internal Medicine, Soonchunhyang University College of Medicine Seoul Hospital, Seoul, South Korea
Search for more papers by this authorJae Young Jang
Department of Internal Medicine, Soonchunhyang University College of Medicine Seoul Hospital, Seoul, South Korea
Search for more papers by this authorHong Soo Kim
Department of Internal Medicine, Soonchunhyang University College of Medicine Cheonan Hospital, Cheonan, South Korea
Search for more papers by this authorCorresponding Author
Sae Hwan Lee
Department of Internal Medicine, Soonchunhyang University College of Medicine Cheonan Hospital, Cheonan, South Korea
Correspondence
Sae Hwan Lee, Liver clinic, Soonchunhyang University School of Medicine, Cheonan Hospital, 31 Soonchunhyang 6gil, Dongnam-gu, Cheonan, Chungnam, 31151, South Korea.
Email: [email protected]
Baek Gyu Jun, Division of Gastroenterology, Department of Internal Medicine, University of Ulsan College of Medicine, Gangneung Asan Hospital, 38, Bangdong-gil, Sacheon-myeon, Gangneung-si, Gangwon-do, South Korea.
Email: [email protected]
Search for more papers by this authorKim and Yang contributed equally to this work.
Funding information
This study was supported by Medical Research Promotion Program through the Gangneung Asan Hospital funded by the Asan Foundation (2019-B07). This study was supported by grants from the Bio & Medical Technology Development Program of the NRF funded by the Korean government, MSIP (2019M3E5D1A02069065)
Abstract
Antiviral therapy improves survival in patients with hepatitis B virus (HBV)-induced hepatocellular carcinoma (HCC). However, the effect of antiviral therapy in patients with low-level viremia HBV-HCC receiving non-curative therapy remains unclear. We aimed to evaluate the role of antiviral therapy in patients with low-level viremia and treated with transarterial chemoembolization (TACE). This retrospective study evaluated 206 patients with HBV-HCC who underwent TACE as an initial treatment. Of those, 135 patients received antiviral therapy (antiviral group), and 71 did not (non-antiviral group). The definition of low-level viremia was an HBV DNA level <2000 IU/ml. Kaplan-Meier curves, log-rank tests and Cox regression analysis were used for statistical analyses. The median follow-up duration was 39 months (1–174 months). Overall survival (OS) did not differ between groups (P = .227). Barcelona Clinic Liver Cancer stage (BCLC), Child-Pugh (CP) class and α-fetoprotein level were independent prognostic factors for OS. Antiviral therapy (hazard ratio [HR], 0.503, P = .022) was a prognostic factor for 2-year survival. On subgroup analysis, antiviral therapy improved short-term survival in patients with BCLC stage 0 and A (P = .037) and CP class A (P = .04). In patients with low-level viremia, antiviral therapy yielded short-term survival benefits, particularly in patients with early-stage HCC.
CONFLICT OF INTEREST
All the authors declare no potential conflicts of interest pertinent to this manuscript.
Open Research
DATA AVAILABILITY STATEMENT
The data that supports the findings of this study are available on request from the corresponding author. The data are publicly available due to privacy or ethical restrictions.
REFERENCES
- 1Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394-424.
- 2Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006; 6: 674-687.
- 3Shin H, Jung YW, Kim BK, et al. Risk assessment of hepatocellular carcinoma development for indeterminate hepatic nodules in patients with chronic hepatitis B. Clin Mol Hepatol. 2019; 25: 390.
- 4 KASL. KASL clinical practice guidelines for management of chronic hepatitis B. Clinical and Molecular. Hepatology. 2019; 25: 93.
- 5Akinyemiju T, Abera S, Ahmed M, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA oncol. 2017; 3: 1683-1691.
- 6 EASL. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018; 69: 182-236.
- 7Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018; 67: 358-380.
- 8Kim GA, Shim J, Kim MJ, et al. Radiofrequency ablation as an alternative to hepatic resection for single small hepatocellular carcinomas. Br J Surg. 2016; 103: 126-135.
- 9Kudo M, Izumi N, Kubo S, et al. Report of the 20th Nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res. 2020; 50: 15-46.
- 10Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013; 58: 98-107.
- 11 EASL. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017; 2017(67): 370-398.
- 12Terrault NA, Lok AS, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018; 67: 1560-1599.
- 13Chan AC, Chok KS, Yuen WK, et al. Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus–related hepatocellular carcinoma. Arch Surg. 2011; 146: 675-681.
- 14Urata Y, Kubo S, Takemura S, et al. Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma. J Hepato-Biliary-Pan Sci. 2012; 19: 685-696.
- 15Yin J, Li N, Han Y, et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol. 2013; 31: 3647-3655.
- 16Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver International. 2015; 35: 2155-2166.
- 17Jang JW, Choi JY, Bae SH, et al. Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol. 2004; 41: 427-435.
- 18Jang JW, Choi JY, Bae SH, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology. 2006; 43: 233-240.
- 19Yu SJ, Lee J-H, Jang ES, et al. Hepatocellular carcinoma: high hepatitis B viral load and mortality in patients treated with transarterial chemoembolization. Radiology. 2013; 267: 638-647.
- 20Lao XM, Luo G, Ye LT, et al. Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma. Liver Internat. 2013; 33: 595-604.
- 21Xu X, Huang P, Tian H, et al. Role of lamivudine with transarterial chemoembolization in the survival of patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2014; 29: 1273-1278.
- 22Shao W, Zhang F, Cong N, et al. The hepatitis B virus reactivation after transarterial chemoembolization in Chinese hepatocellular carcinoma patients with low serum hepatitis B virus DNA level. Ther Clin Risk Manag. 2015; 11: 1367.
- 23Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018; 68: 723-750.
- 24Lencioni R, Llovet JM. Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma. Sem Liver Dis. 2010; 30(01): 52-60.
- 25Jun BG, Kim SG, Kim YD, et al. Combined therapy of transarterial chemoembolization and stereotactic body radiation therapy versus transarterial chemoembolization for≤5cm hepatocellular carcinoma: Propensity score matching analysis. PLoS One. 2018; 13:e0206381.
- 26Toyoda H, Kumada T, Tada T, et al. Transarterial chemoembolization for hepatitis B virus–associated hepatocellular carcinoma: improved survival after concomitant treatment with nucleoside analogues. J Vasc Interv Radiol. 2012; 23: 317-322.
- 27Zhou Z-G, Zheng X-R, Zhou Q, et al. Impact of oral anti–hepatitis B therapy on the survival of patients with hepatocellular carcinoma initially treated with chemoembolization. Chinese J Can. 2015; 34: 14.
- 28Wong GH, Tse YK, Chan HY, et al. Oral nucleos (t) ide analogues reduce recurrence and death in chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther. 2016; 43: 802-813.
- 29Li B, Chen A, Du X, et al. Influence of antiviral therapy on survival of patients with hepatitis B-associated hepatocellular carcinoma undergoing transarterial chemoembolization. Trop J Pharm Res. 2017; 16: 1997-2005.
- 30Jian Z-W, Wu X-W, Chen Z-X, et al. Effect of Nucleos (t) ide Analogs on Patients with Intermediate and Advanced Hepatitis B Virus-Related Hepatocellular Carcinoma. Dig Dis Sci. 2019; 64: 2187-2198.
- 31Sohn W, Kang TW, Choi S-K, et al. Effect of oral antiviral treatment on long-term outcomes of radiofrequency ablation therapy for hepatitis B virus-related hepatocellular carcinoma. Oncotarget. 2016; 7: 47794.
- 32Yang T, Lu J-H, Zhai J, et al. High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study. European J Surg Oncol. 2012; 38: 683-691.
- 33Hann HW, Coben R, Brown D, et al. A long-term study of the effects of antiviral therapy on survival of patients with HBV-associated hepatocellular carcinoma (HCC) following local tumor ablation. Cancer Med. 2014; 3: 390-396.
- 34Chong C, Wong G, Wong V, et al. Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: a prospective-retrospective study. Aliment Pharmacol Ther. 2015; 41: 199-208.
- 35Xu L, Gao H, Huang J, et al. Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib. J Gastroenterol Hepatol. 2015; 30: 1032-1039.
- 36Yang Y, Wen F, Li J, et al. A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib. Liver Intern. 2015; 35: 2147-2154.
- 37Wang K, Jiang G, Jia Z, et al. Effects of transarterial chemoembolization combined with antiviral therapy on HBV reactivation and liver function in HBV-related hepatocellular carcinoma patients with HBV-DNA negative. Medicine. 2018; 97:e10940.
Citing Literature
